Dexamethasone

Description générale

Dexamethasone is a corticosteroid used in the treatment of various conditions where corticosteroids are indicated, including pain and oedema due to malignancy, nausea and vomiting, and in treatment protocols for some blood tissue cancers.

INN	Dexamethasone
Codes ATC	H02AB02 C05AA09 L01AA01
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 1977 (TRS 615) pour Lymphoid leukaemia, not elsewhere classified Modifié en 1984 (TRS 722) pour Allergic or hypersensitivity conditions of unspecified type Modifié en 1991 (TRS 825) pour Palliative care Modifié en 2009 (TRS 958) pour Nausea or vomiting Modifié en 2013 (TRS 985) pour Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy Modifié en 2019 (TRS 1021) pour Plasma cell myeloma Modifié en 2021 (TRS 1035) pour Burkitt lymphoma including Burkitt leukaemia Modifié en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-negative Modifié en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-positive
Wikipédia	Dexamethasone
DrugBank	Dexamethasone

Recommandations

Section Hormones and antihormones

- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
- Oral > Solid > tablet: 4 mg (as dexamethasone base)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)

Indications

Lymphoid leukaemia, not elsewhere classified

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Section Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Indications

Allergic or hypersensitivity conditions of unspecified type

Section Antiemetic medicines

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)

Indications

Nausea or vomiting

Section Other medicines administered to the mother

- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Section Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equialent to 3.3 mg dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)

Indications

Palliative care